Vaccine Therapy Compared With Interferon Alfa in Treating Patients With Stage III Melanoma
NCT00003715
Terminated
RATIONALE: Vaccines made from a person's melanoma cells may make the body build an immune response to kill tumor cells. Interferon alfa may interfere with the growth of the cancer cells. PURPOSE: Randomized phase III trial to compare the effectiveness of melanoma vaccine with that of interferon alfa-2b in treating patients who have stage III melanoma that has spread to regional lymph nodes following surgery.
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
12/02/2015
Locations: Cancer and Blood Institute of the Desert, Rancho Mirage, California +16 locations
Conditions: Melanoma (Skin)
Register for Updates
Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Brain Tumor
NCT00003273
Withdrawn
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of different regimens of combination chemotherapy followed by peripheral stem cell transplantation in treating children who have newly diagnosed brain tumor.
Gender:
ALL
Ages:
10 years and below
Trial Updated:
11/30/2015
Locations: Cancer Research Center of Hawaii, Honolulu, Hawaii +18 locations
Conditions: Brain and Central Nervous System Tumors, Neuroblastoma, Retinoblastoma, Sarcoma
Register for Updates
Trial to Evaluate Genomic Expression Profiles to Direct Preoperative Chemotherapy in Early Stage Breast Cancer
NCT00636441
Terminated
This multi-center randomized Phase II study assigned HER2-negative early-stage breast cancer patients to receive preoperative systemic chemotherapy in either a "genomic-guided" arm or a "non-guided arm." The "genomic-guided" method (Arm 1) used genomic expression profiling to assign the preoperative therapy (Doxorubicin/Cyclophosphamide (AC) versus Docetaxel/Cyclophosphamide (TC), while Arm 2 used random assignment to these two therapies.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
11/16/2015
Locations: Duke University Medical Center, Durham, North Carolina
Conditions: Early-Stage Breast Cancer
Register for Updates
Combined Kidney and Bone Marrow Transplantation to Prevent Kidney Transplant Rejection
NCT00801632
Completed
In small initial studies, combined kidney and bone marrow transplants from the same donor have permitted some individuals to stop taking anti-rejection medicines without rejecting their transplant. This clinical trial will study this method in a greater number of people to determine if it is indeed effective and safe.
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
11/06/2015
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Kidney Transplantation, Kidney Failure, Chronic
Register for Updates
Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Blastic Phase Chronic Myelogenous Leukemia
NCT01670084
Withdrawn
In this study researchers want to find out more about the side effects of a new drug for Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) and chronic myelogenous leukemia (CML) blastic phase (BP) and if this disease will respond better to nilotinib combined with standard hyper-CVAD therapy rather than hyper-CVAD alone. Hyper-CVAD is a combination of cyclophosphamide, mesna, vincristine (vincristine sulfate), doxorubicin (doxorubicin hydrochloride), dexamethasone, methotr... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
10/29/2015
Locations: Mayo Clinic in Arizona, Scottsdale, Arizona +1 locations
Conditions: B-cell Adult Acute Lymphoblastic Leukemia, Blastic Phase Chronic Myelogenous Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia, Untreated Adult Acute Lymphoblastic Leukemia
Register for Updates
Cell Therapy for Metastatic Melanoma Using CD8 Enriched Tumor Infiltrating Lymphocytes
NCT01236573
Terminated
Background: - One experimental treatment for certain types of cancer is cell therapy, which involves collecting lymphocytes (white blood cells) from a tumor, growing them in the laboratory in large numbers, and then modifying the cells with a gene (interleukin-12 (IL-12)) that stimulates the immune system to attack and destroy the cancer cells. Because this treatment is experimental, researchers are interested in determining the side effects and overall effectiveness of cell therapy using white... Read More
Gender:
ALL
Ages:
Between 18 years and 66 years
Trial Updated:
10/26/2015
Locations: National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland
Conditions: Skin Cancer, Metastatic Melanoma
Register for Updates
UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy
NCT00083551
Completed
This study has been designed to evaluate whether "anti-angiogenesis" therapy with thalidomide and whether additional chemotherapy after transplant will be beneficial. Another objective is to find out what kinds of side effects occur with this combination of treatment and how often they occur.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
10/21/2015
Locations: University of Arkansas for Medical Sciences/MIRT, Little Rock, Arkansas
Conditions: Multiple Myeloma
Register for Updates
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
NCT00409188
Completed
The purpose of this study is to determine whether the cancer vaccine tecemotide (L-BLP25) in addition to best supportive care is effective in prolonging the lives of subjects with unresectable stage III non-small cell lung cancer, compared to best supportive care alone. A local ancillary (sub) study in European centers will evaluate the immune response in peripheral blood after tecemotide (L-BLP25) or placebo vaccination.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/19/2015
Locations: Saint Edward Mercy Medical Center, Fort Smith, Arkansas +294 locations
Conditions: Non-small Cell Lung Cancer
Register for Updates
Melanoma Treatment With White Blood Cells That Destroy MART Expressing Tumor Cells
NCT01495572
Terminated
Background: - Some cancer treatments collect a patient s own blood cells to use as specialized cancer-fighting cells. Collected white blood cells known as PBL (peripheral blood lymphocytes) can use to isolate special cells that can fight tumors. Before treatment with PBL, chemotherapy is given to destroy existing white blood cells so that the new cells can survive and attack the tumors. After PBL treatment, aldesleukin is given to help the new cells grow. Researchers want to see if special whit... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/13/2015
Locations: National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland
Conditions: Metastatic Melanoma, Skin Cancer
Register for Updates
R-MACLO-IVAM and Thalidomide in Untreated Mantle Cell Lymphoma
NCT00450801
Completed
RATIONALE: To evaluate the efficacy of a new high intensity chemotherapy regimen with thalidomide maintenance in patients with newly diagnosed mantle cell lymphoma PURPOSE: This phase II trial is studying how well giving rituximab together with combination chemotherapy followed by thalidomide works in treating patients with previously untreated mantle cell lymphoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/12/2015
Locations: University of Miami Sylvester Comprehensive Cancer Center - Miami, Miami, Florida
Conditions: Lymphoma
Register for Updates
Neoadjuvant TAC Plus or Minus Bevacizumab(AVF3299)
NCT00203372
Completed
The purpose of this study is to evaluate the safety of the TAC-bevacizumab combination and investigate whether changes in gene expression, or the expression of specific biomarkers, are either predictive of response to bevacizumab or indicative of response.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
10/09/2015
Locations: UCLA Medical Center, Los Angeles, California +8 locations
Conditions: Breast Cancer
Register for Updates
Radiation, Chemotherapy, Vaccine and Anti-MART-1 and Anti-gp100 Cells for Patients With Metastatic Melanoma
NCT00923195
Completed
Background: * Melanoma antigen recognized by T-cells (MART-1) and gp100 are two genes found in melanoma cells. An experimental procedure developed for treating patients with advanced melanoma uses these genes and a type of virus to make special cells called anti-MART-1 and anti-gp100 cells, which are designed to destroy the patient's tumor. The cells are created in the laboratory using the patient's own tumor cells or blood cells. * The procedure also uses one of two vaccines-the anti-MART-1 pe... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/06/2015
Locations: National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland
Conditions: Melanoma, Skin Cancer
Register for Updates